Features

The CDMO/CMO sector had a major shakeup with Novo Holdings, the parent company of Novo Nordisk, announcing it had agreed to acquire Catalent for $16.5 billion. What is the strategy behind the deal and the implications on a manufacturing basis?

Which CDMOs/CDMO are expanding manufacturing capacity for intermediates and small-molecule active pharmaceutical ingredients (APIs)? DCAT Value Chain Insights gives a roundup of recently announced, in-progress, and completed expansions.

How did the industry fare with new drug approvals in 2023? What do the numbers show? Are approvals in pace with prior years, and what is the mix between small molecules and biologics? Which companies and products made the mark?

The US government is sending initial offers to participating bio/pharmaceutical companies of the first 10 Rx drugs selected for negotiation in the first cycle of the Medicare Drug Price Negotiation Program. Which companies & products are affected? 

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

What are they key issues impacting bio/pharmaceutical manufacturing & supply in 2024? What technology may be a game-changer or moves that will be most noteworthy across the bio/pharma manufacturing value chain? DCAT Value Chain Insights takes an inside look.

What is on the industry’s radar for 2024?  See what issues make DCAT Value Chain Insights’ list—more established trends and those that may be under the industry’s radar: from growth prospects in the bio/pharma market, to key factors shaping drug development, and what may on the horizon for manufacturing and the supply chain.

The European Commission has launched the Critical Medicines Alliance, an EU-level initiative to develop recommendations and provide advice to EU policy decision-makers on how to address long-standing medicines shortages, including ways to shore up domestic manufacturing in the EU and strengthen the bio/pharma supply chain.

What can CDMOs/CMOs expect in 2024? DCAT Value Chain Insights examines key trends, fundamentals, and the variables influencing the sector’s performance.

At the J.P. Morgan Annual Healthcare Conference in San Francisco this week, bio/pharma industry executives outlined their key pipeline contenders and commercial products. How do mergers and acquisitions play in their strategies?